In a filing, Greenwich LifeSciences Inc revealed its CEO and CFO Patel Snehal acquired Company’s shares for reported $53694.0 on Jan 13 ’26. In the deal valued at $29.83 per share,1,800 shares were bought. As a result of this transaction, Patel Snehal now holds 5,604,102 shares worth roughly $119.31 million.
Then, Patel Snehal bought 2,900 shares, generating $79,866 in total proceeds. Upon buying the shares at $27.54, the CEO and CFO now owns 5,602,302 shares.
Before that, Patel Snehal bought 4,300 shares. Greenwich LifeSciences Inc shares valued at $91,848 were divested by the CEO and CFO at a price of $21.36 per share. As a result of the transaction, Patel Snehal now holds 5,599,402 shares, worth roughly $119.21 million.
Noble Capital Markets initiated its Greenwich LifeSciences Inc [GLSI] rating to an Outperform in a research note published on August 20, 2025; the price target was $45. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating.
Price Performance Review of GLSI
On Tuesday, Greenwich LifeSciences Inc [NASDAQ:GLSI] saw its stock fall -14.43% to $21.29. Over the last five days, the stock has lost -20.65%. Greenwich LifeSciences Inc shares have risen nearly 69.37% since the year began. Nevertheless, the stocks have risen 1.33% over the past one year.
How much short interest is there in Greenwich LifeSciences Inc?
A steep rise in short interest was recorded in Greenwich LifeSciences Inc stocks on 2025-12-31, growing by 59376.0 shares to a total of 1.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 1.61 million shares. There was a rise of 3.56%, which implies that there is a positive sentiment for the stock.
